FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bassler Bonnie L						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]								neck all appli	cable)	Person(s) to Is				
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 06/05/2024								below		below				
(Street) TARRYTOWN NY 10591					- 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City) (State) (Zip)							Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Dat						tion 2A. Deemed Execution Date, if any			3. Trans	<del>-                                    </del>			ed (A) or	5. Amou	unt of	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial			
					(,			(Month/Day/Year)		v	Amount	(A) or (D)	Price	Owned Reporte Transac (Instr. 3	ed etion(s)	(l) (Instr. 4)	Ownership (Instr. 4)			
Common Stock 06/05/2					/2024	.024			M <sup>(1)</sup>		827	A	\$380.9	95 2,	209	D				
Common Stock 06/05/2					/2024	2024			<b>S</b> <sup>(1)</sup>		827	7 D \$1,		.1 1,	1,382					
		1	able II -								osed of converti			y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution if any	3A. Deemed Execution Date, if any (Month/Day/Year)		iction Instr.	of Deriv Secu Acqu (A) o Disp of (D	osed ) r. 3, 4	6. Date E Expiration (Month/I	n Dat	Amount o		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares							
Non- Qualified Stock Option (right to buy)	\$380.95	06/05/2024			M <sup>(1)</sup>			827	(2)		01/02/2028	Common Stock	827	\$0.0	0	D				

## **Explanation of Responses:**

- $1.\ Disposition/acquisition\ made\ pursuant\ to\ a\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1(c)\ adopted\ on\ February\ 27,\ 2024.$
- 2. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

<u>/s/\*\*Bonnie L. Bassler</u> <u>06/06/2024</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.